Rapport Therapeutics clocked its second Phase 2 win in 14 months for RAP-219—which the company is positioning as a potential ...

The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score ...

I feel like I can do anything right now.” “Why is everyone else so slow?”When you type “bipolar disorder” into a search bar, ...

Johnson & Johnson JNJ on Monday reported topline results from its Phase 3 study evaluating Caplyta (lumateperone) for adults experiencing manic episodes linked to bipolar I disorder. The trial ...

Mania, in which mood and energy level are extremely elevated for at least a week, and hypomania, which is less severe and lasts at least four days, are the defining features of bipolar spectrum ...

The Phase 3 randomized, double-blind study evaluated once-daily CAPLYTA ® 42mg versus placebo over three weeks in adults with manic episodes, with or without mixed features, associated with bipolar I ...

Iloperidone, a second-generation antipsychotic used to treat schizophrenia, appears to be safe and effective in the treatment of bipolar mania, new research suggested. Results of the phase 3 ...

Dysphoric mania is a combination of mania and depression symptoms. Though its causes are unclear, treatment includes medication and talk therapy. Bipolar disorder sometimes features dysphoric mania.